• Manuscript type: Research Article

# **Title page**

# Role of Hemogram-Derived Ratios and Systemic-Immune Inflammation Index in Prediction of COVID-19 Progression in Egyptian Patients

Running title: Hemogram Ratios in COVID-19 Progression.

# **Authors:**

# Sara I. Taha<sup>a\*</sup>, Sara F. Samaan<sup>b</sup>, Shereen A. Baioumy<sup>c</sup>, Aalaa K. Shata<sup>d</sup>, Mariam K. Youssef<sup>a</sup>

- a. Department of Clinical Pathology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
- b. Department of Internal Medicine, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
- c. Department of Microbiology and Immunology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
- d. Department of Pulmonary Medicine, Faculty of Medicine, Ain Shams university, Cairo, Egypt.

#### Authors:

## Sara Ibrahim Taha\*

Degree: MD Clinical Pathology/Immunology

Lecturer of Clinical Pathology/ Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. E-mail: <u>dr\_sara\_ib@med.asu.edu.eg</u>

#### Sara Farid Samaan

Degree: MD Internal Medicine

Lecturer of Internal Medicine, Faculty of Medicine, Ain Shams university, Cairo, Egypt.

## E-mail: Dr.sara\_farid@yahoo.com

## Shereen Atef Baioumy

Degree: MD Microbiology and Immunology

Lecturer of Microbiology and Immunology, Zagazig University, Zagazig, Egypt.

Email: drshereenatef@yahoo.com

## Aalaa Kamal Shata

Degree: MD Pulmonary medicine

Lecturer of Pulmonary Medicine, Faculty of Medicine, Ain Shams university, Cairo, Egypt.

# E-mail: aalaashata@yahoo.com

## Mariam Karam Youssef

Degree: MD Clinical Pathology/Hematology Lecturer of Clinical Pathology/Hematology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt. E-mail: <u>Dr.mariam\_karam@hotmail.com</u>

## \* Corresponding Author:

Sara Ibrahim Taha, MD, PhD Lecturer of Clinical Pathology/ Immunology, Faculty of Medicine, Ain Shams University. Address: Ain Shams University, Abassia, Cairo, Egypt Office tel., fax: + (202) 24346308 Mobile: + (20) 1125360009 E-mail: <u>dr\_sara\_ib@med.asu.edu.eg</u> https://orcid.org/0000-0001-8224-8701

### 1 Abstract

2 Background: Early detection of COVID-19 patients with potentially severe disease is crucial for predicting the disease's course and prioritizing medical resources, lowering 3 overall disease mortality. **Objectives:** To explore the role of hemogram-derived ratios 4 5 and systemic-immune inflammation index (SII), in addition to C-reactive protein (CRP), in predicting COVID-19 severity and prognosis. Methods: In this retrospective study, 6 data were collected from the medical records of 425 COVID-19 patients. Neutrophil-to-7 8 lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and SII, together with the 9 CRP, were investigated and compared. Results: NLR, PLR, SII, and CRP increased 10 significantly in severe cases and with ICU admission ( $p \le 0.001$ ). But, in non-survivors only NLR and CRP were significantly elevated (p < 0.05). By interpreting area under the 11 receiver operating characteristic curve (ROC-AUC), CRP and NLR were better 12 predictors of disease severity (AUC: 0.7 for both), the need for ICU admission (AUC: 13 14 0.763 and 0.727, respectively) and in-hospital mortality (AUC: 0.812 and 0.75, 15 respectively). SII was significantly associated with the risk of severe disease development 16 (odds ratio (OR): 3.143; 95% confidence interval (CI): 1.101-8.976); CRP (OR: 2.902; CI95%: 1.342-6.273) and NLR (OR: 2.662; CI95%, 1.072-6.611) were significantly 17 18 associated with ICU admission risk; and only CRP was significantly associated with in-19 hospital mortality risk (OR: 3.988; CI95%: 1.460-10.892). Conclusions: Values of CRP, SII, and NLR at the time of hospital admission could be independent prognostic 20 biomarkers to predict COVID-19 progression. The integration of CRP, SII, and NLR into 21 22 prognostic nomograms may lead to improved prediction.



Keywords: Coronavirus; Inflammation index; Lymphocyte ratio; Mortality; Progression.

# 24 INTRODUCTION:

Fatal coronavirus, named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has caused novel corona virus disease (COVID-19) which first broke out in December 2019 in Wuhan, China [1]. Fever, dry cough, and fatigue are the main manifestations of 28 COVID-19. In more severe cases, patients often have dyspnea and/or hypoxemia that can 29 rapidly progress to acute respiratory distress syndrome, septic shock, metabolic acidosis, 30 coagulation dysfunction, and multiple organ failure [2].

31 Although the majority of COVID-19 patients have been classified as mild cases that can 32 recover shortly after appropriate clinical intervention, rapid severe progression of the disease can occur with increasing rates of hospitalization, ICU admission and mortality 33 [3]. Furthermore, not all COVID-19 patients have symptoms in the early stage of the 34 35 disease, making early tracking of suspected cases very important [4]. Neither the detection capability of viral nucleic acid kits nor the popular rate of pulmonary imaging 36 can support large-scale screening of all populations. In the current novel corona virus 37 pandemic, if the most routine and inexpensive peripheral blood tests have characteristic 38 changes for infected patients, especially those with severe infections, they will be very 39 40 helpful for proper early clinical intervention to reduce the mortality of patients. Complete blood count (CBC) is the most widely performed, cost effective test that can be 41 performed in almost all laboratories, even in those with limited equipment [4]. 42

In this study, the role of peripheral CBC derived biomarkers (NLR, PLR, SII) together
with the CRP at hospital admission, has been examined to predict the progression and the
outcome of COVID-19 infection in a cohort of Egyptian patients.

# 47 MATERIALS AND METHODS

# 48 **Patient selection:**

This retrospective study was conducted in line with research regulations, including the approval of Ain-Shams University Faculty of Medicine Research Ethics Committee (REC). Data were acquired anonymously from hospital records and kept private and confidential. They were only used for study purposes.

53 We randomly selected 425 COVID-19 patients admitted to Quarantine Hospitals of Ain-54 Shams University (El-Obour Ain Shams University Specialized Hospital and Eldemerdash Hospital), Cairo, Egypt, between February and April, 2021. COVID-19 55 infection was confirmed in all cases by a positive reverse transcription polymerase chain 56 57 reaction (RT-PCR) test result for nasal and pharyngeal swab specimens. Only patients 58 above the age of 18 years were included in the study. The study excluded pregnant women and patients with aplastic anemia, lymphoproliferative or myeloproliferative 59 disorders, immune deficiency, and a history of taking drugs that affect blood cell counts 60 such as epinephrine, thyroxin, or corticosteroids. 61

# 62 Data collection:

Demographic and clinical data were collected from the medical records of the patients, including: age, gender, clinical presentation, detailed medical and drug history, presence of co-morbidities, need for ICU admission and patients' outcome. Also, on admission, laboratory findings were collected and analyzed, including CBC with differential counts and CRP. Blood cell ratios and indexes of systemic inflammation were calculated,

68 including: the NLR (neutrophil/lymphocyte ratio), PLR (platelet/lymphocyte ratio) and

69 SII ((neutrophils × platelets)/lymphocytes).

Categorization of patients was done in accordance with guidelines of Ain Shams
University Hospitals Consensus Statement on Management of Adult COVID-19 Patients
[5].

# 73 Statistical analysis:

74 Categorical variables were analyzed using the Chi-square test and were expressed as a 75 number and percentage. For analysis of the parametric variables, the independent samples 76 t-test was used and they were presented as a mean and standard deviation. Non-77 parametric variables were analyzed by the Mann-Whitney U test and presented as the 78 median and interquartile range (IQR). The ROC curve analysis was used to assess the 79 predictive performance of the significant parameters. To analyze the association between 80 the COVID-19 severity, need for ICU admission or in-hospital mortality, and related 81 factors, univariate and multivariate analyses were carried out using a logistic regression 82 model. The statistical analysis of the data was performed using SPSS version 20.0 83 software. A p value of  $\leq 0.05$  was considered statistically significant.

### 84 **RESULTS**

# 85 Demographic and cinical characteristics of the entire study cohort:

A total of 425 adult patients (227 females and 198 males) with confirmed COVID-19 infection were included in this study. Of them, 188 (44.2%) patients were mild, while 237 (55.8%) were moderate/severe cases. The mean age was 47.90 ± 17.08 years. Hypertension (34.1%) and diabetes (30.4%) were the most common co-morbidities. Only

90 112 (26.4%) patients required ICU admission. Of all studied subjects, 385 (90.6%)
91 patients were discharged alive, whereas the remaining 40 (9.4%) died. The median
92 hospitalization duration was 10 days (IQR: 6 – 17). The baseline characteristics of the
93 included patients are shown in tables 1 (a) and 2 (a).

## 94 Clinical variables associated with disease severity:

95 **Table 1** (b) summarizes the characteristics of the mild (n = 188) and moderate/severe (n = 237) groups. The mean age of the moderate/severe group was significantly higher than 96 that of the mild group (53.47 years  $\pm$  16.10 vs. 40.84 years  $\pm$  15.65; p < 0.05), with no 97 statistically significant difference in gender between both groups (p > 0.05). Of the 98 moderate/severe group, 108 (45.6%) patients required ICU admission and 40 (16.9%) 99 100 patients died. In contrast, of the mild group, only 4 (2.1%) patients required ICU 101 admission and no deaths occurred. The moderate/severe group had a statistically significant longer length of hospital stay when compared to the mild group (14 days 102 103 (IQR: 9 - 20) vs 7 days (IQR: 5 - 10),  $p \le 0.001$ ).

**Table 2 (b)** shows that co-morbidities including chronic obstructive pulmonary disease (COPD), diabetes mellitus, hypertension, chronic liver disease, chronic kidney disease and ischemic heart disease were significantly associated with disease severity ( $P \le 0.001$ )

107 The moderate/severe group had statistically significant lower hemoglobin and 108 lymphocyte count but statistically significant higher total leukocytic count (TLC), PLR, 109 NLR, SII and CRP when compared to the mild group (P < 0.05). Platelet and neutrophil 110 counts were not significantly different between groups (p > 0.05). **Table 3 (b)** 

### 111 Clinical variables associated with ICU admission:

The mean age of the ICU group (n=112) was significantly higher than that of the non-ICU group (n=313) (56.83 years  $\pm$  15.75 vs. 44.70 years  $\pm$ 16.41; p  $\leq$  0.001), but no statistically significant difference in gender was found between the groups (p > 0.05). The ICU group had a statistically significant longer length of hospital stay when compared to the non-ICU group (19 days (IQR: 9 – 22) vs 9 days (IQR: 6 – 13), p  $\leq$ 0.001). Of the ICU group, 108 (96.4%) patients were moderate/severe and 4 (3.6%) patients were mild. Only 39 (34.8%) patients of the ICU group died. **Table 1 (c)** 

119 All the previously mentioned co-morbidities were significantly associated with ICU

admission (P  $\leq$  0.001) except chronic liver disease (p > 0.05). Table 2 (c)

121 Similar to the moderate/severe group, the ICU group had statistically significant lower

hemoglobin and lymphocyte count but statistically significant higher TLC, PLR, NLR,

123 SII and CRP when compared to the non-ICU group ( $P \le 0.001$ ). Platelet and neutrophil

124 counts were not significantly different between groups (p > 0.05). Table 3 (c)

# 125 Clinical variables associated with in-hospital mortality:

**Table 1 (d)** summarizes the demographic and clinical characteristics for survivors (n=385) and non-survivors (n=40). Non-survivors were significantly older than survivors (mean age: 60.30 years  $\pm$  13.60 vs. 46.61years  $\pm$  16.90; p  $\leq$  0.001) with no significant gender difference. They had a statistically significant longer length of hospital stay when compared to survivors (18 days (IQR: 7 – 22) vs 10 days (IQR: 6 – 15), p < 0.05).

**Table 2 (d)** shows that chronic liver disease was not significantly associated with inhospital mortality (p > 0.05) but the other mentioned comorbidities did (p < 0.05).

- 133 Non-survivors had statistically significant higher TLC, NLR and CRP when compared to
- the survivors (P < 0.05). Hemoglobin, platelet count, lymphocyte count, neutrophil count,
- PLR and SII were not significantly different between groups (p > 0.05). Table 3 (d)

# 136 **Prediction of disease severity, ICU admission and in-hospital mortality:**

**Table 4** shows the independent prediction ability of the studied biomarkers and the 137 optimal cut-off values calculated by the ROC analysis. As regards COVID-19 severity 138 prediction, CRP AUC was 0.707 with a cut off value of 12 mg/L, sensitivity of 65.66% 139 140 and specificity of 69.31%, followed by NLR, SII and PLR with AUC of 0.700, 0.669 and 0.640, and cut-off values of 4.33, 1012.36 and 185, respectively. Regarding ICU 141 142 admission prediction, CRP AUC was 0.763 with a cut off value of 115 mg/L, sensitivity 143 of 54.76% and specificity of 94.30%, followed by NLR, SII and PLR with AUC of 0.727, 0.717 and 0.580, and cut-off values of 4.5, 668.57 and 300, respectively. For in-144 145 hospital mortality prediction, CRP AUC was 0.812 with a cut off value of 141 mg/L, sensitivity of 70% and specificity of 95.56%, followed by NLR with AUC of 0.751 and a 146 147 cut off value of 4.5. Figures 1-3

# 148 Association with Disease Severity, ICU Admission and In-Hospital Mortality:

To identify factors that may affect the disease severity, ICU admission or in-hospital mortality, we obtained the odds ratios (OR) after conducting logistic regression analysis. The multivariate analysis showed that SII (OR, 3.143; 95% CI, 1.101-8.976; P < 0.05) was significantly positively associated with the disease severity, CRP (OR, 2.902; 95% CI, 1.342-6.273; P < 0.05) and NLR (OR, 2.662; 95% CI, 1.072-6.611; P < 0.05) were significantly positively associated with the need for ICU admission, and only CRP (OR,

155 3.988; 95% CI, 1.460-10.892; P < 0.05) was significantly positively associated with in-

156 hospital mortality. **Table 5** 

## 157 **DISCUSSION**

Since hyper-inflammatory state has been incriminated in the patho-physiology of COVID-19, information about inflammation and the immune response of patients with different disease severity should be continuously explored for predicting the progression of the disease and improving the outcome of patients [1]. Complete blood counts are the most easily performed tests in a time and cost-effective manner. Included in the CBC are values that can be used as effective inflammatory biomarkers [4].

Neutrophils can be triggered by virus-related inflammatory factors to release large amounts of reactive oxygen species and other cytotoxic mediators, which may dampen the virus. Moreover, neutrophils are able to release neutrophil extracellular traps that help in capturing and damaging different pathogens, including viruses [6].

On the other hand, severe cases of viral infection can result in lymphocyte exhaustion, because viruses can directly attack and damage target cells; also, they can activate immune cells to participate in the anti-viral process, resulting in severe lymphocyte damage and apoptosis. Because systemic inflammation stimulates neutrophil production and accelerates lymphocyte apoptosis, virus-triggered inflammation raises the NLR ratio [6].

Additionally, as platelets have an important role in the regulation of various inflammatory processes, both the NLR and PLR indirectly reflect a patient's inflammatory state [7]. In recent years, NLR and PLR have been validated as prognostic

biomarkers in various disorders including cardiac conditions, solid tumors, sepsis,pneumonia, and acute respiratory distress syndrome [8].

A recently proposed score is the SII, which is an index defining the instability in the inflammatory response. SII has been proposed as a prognostic indicator in the follow-up of patients with sepsis and in a number of tumors including small cell lung and hepatocellular carcinomas [7].

The current study is aimed at exploring the role of NLR, PLR, and SII, in addition to the CRP in predicting severity of the disease, the need for ICU admission and in-hospital mortality in COVID-19 patients.

We found a significant relation between advancing patients' ages and the severity of the 186 disease as well as the rate of ICU admission and in-hospital mortality. However, these 187 188 could not be linked to a specific gender. Our findings were consistent with the studies of 189 Yang et al. and Fois et al. [4], [9], who reported significantly advanced age and non-190 significant difference in gender in the more severe cases and the non-survivors, 191 respectively. However, our study was only partially consistent with Wang and colleagues [10] who reported non-significant differences in age or gender with the progression of the 192 193 disease. Similar to the study of Yang et al. [4], we found the overall incidence of co-194 morbidities (diabetes, hypertension, kidney dysfunction) to be significantly higher in the more severe cases. However, partially contrary to the study of Fois et al. [9], who found 195 196 only a significant association between heart disease and COVID-19 mortality and a nonsignificant association between disease mortality and the other co-morbidities including 197 smoking, diabetes, and kidney disease, we found that in-hospital disease mortality was 198 199 significantly higher in patients with diabetes, hypertension, kidney and heart diseases.

Our study also showed a significant increase in NLR, PLR, SII, and CRP in the more 200 severe cases and in those who required ICU admission. However, only NLR and CRP 201 were significantly elevated in patients who died from the disease. This was in accordance 202 203 with the study of Yang and colleagues [4] who reported higher NLR. PLR and CRP in the more severe cases of the disease. However, partially consistent with our study, Fois 204 and colleagues [9] reported significant elevation in NLR and SII in the non-survivor 205 206 group of the disease; they also reported that SII might specifically reflect the pulmonary 207 damage occurring in COVID-19 patients.

Our study revealed that the best cut-off points to predict disease severity and the need for 208 ICU admission were, CRP > 12mg/l & > 115mg/l, NLR > 4.33 & > 4.5, SII > 1012.36 & 209 210 > 668.57, and PLR > 185 & > 300, respectively. Also, the best cut-off points to predict in-hospital mortality were CRP > 145 mg/l and NLR > 4.5. In view of our data, 4 of the 211 188 included mild cases required ICU admission during their hospital stay. This resulted 212 in lowering the SII cut-off point of the need for ICU admission prediction compared to 213 214 that used to predict the disease severity. Furthermore, by multivariate regression analysis, 215 the SII was the best independent biomarker associated with disease severity; CRP and NLR were the best independent predictors of the need for ICU admission; and only CRP 216 was significantly associated with the risk of in-hospital mortality. Yang and Co-workers 217 218 [4] found that both NLR and PLR were independent predictors of disease severity and 219 progression in their studied COVID-19 patients. Also, Fois and colleagues [9] found in 220 their study that the SII was the only independent biomarker to predict in-hospital 221 mortality of COVID-19 patients.

222 One limitation in our study was its retrospective design that could not keep up with the dynamic nature of the disease; more prospective studies with serial determination of 223 biomarkers' levels at different disease stages are still required for better definition of the 224 cut off points that could predict the progression of the disease our study was its 225 retrospective design that could not keep up with the dynamic nature of the disease; more 226 prospective studies with serial determination of biomarkers' levels at different disease 227 228 stages are still required for better definition of the cut off points that could predict the 229 progression of the disease.

# 230 CONCLUSIONS:

Elevated CRP, SII, and NLR were found to be independent prognostic biomarkers that could predict COVID-19 progression. The integration of CRP, SII, and NLR into prognostic nomograms may lead to improved prediction. While CRP along with other inflammatory markers like ESR, LDH, ferritin, and procalcitonin are frequently measured in COVID-19 patients, SII and NLR can be easily calculated using a differential CBC and are cost effective, especially for third world countries.

## 237 Abbreviations:

NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; RT-PCR, reverse
transcription polymerase chain reaction; SARS-CoV-2, severe acute respiratory
syndrome coronavirus-2; SII, systemic immune-inflammation index.

241 Manuscript word count: 2515 words.

# 242 Abstract word count: 243 words

## 243 **Tables:** 5

# 244 **Figures:** 3

**Funding sources:** This research did not receive any specific grant from funding agencies

in the public, commercial, or not-for-profit sectors.

247 Acknowledgement: None.

248 **Conflicts of interest:** The authors declare that there is no conflict of interest regarding the 249 publication of this article.

250 Consent for publication: Not applicable.

251 **Availability of data and materials:** All data needed to support the current findings will be 252 available upon request.

253 Author contributions: *Sara I. Taha*: conceptualization, methodology, software; *Sara F.* 254 *Samaan and Aalaa K. Shata:* investigation, data collection. *Shereen A. Baioumy* 255 visualization, supervision. *Mariam K. Youssef:* writing- reviewing and editing, validation 256 and original draft preparation.

#### 257 **REFERENCES**

258 [1] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. China Novel Coronavirus

259 Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in

- 260 China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733. doi:
- 261 10.1056/NEJMoa2001017. Epub 2020 Jan 24. PMID: 31978945; PMCID: PMC7092803.
- [2] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical
  characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a

- descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-
- 265 6736(20)30211-7. Epub 2020 Jan 30. PMID: 32007143; PMCID: PMC7135076.
- [3] Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia predicts
  disease severity of COVID-19: a descriptive and predictive study. Signal Transduct
  Target Ther. 2020 Mar 27;5(1):33. doi: 10.1038/s41392-020-0148-4. PMID: 32296069;
  PMCID: PMC7100419.
- [4] Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, dNLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020 Jul; 84:106504. doi:
  10.1016/j.intimp.2020.106504. Epub 2020 Apr 13. PMID: 32304994; PMCID:
  PMC7152924.
- [5] Abdelfattah AB, Ahmed S, El-Zahapy H, Al Said A, Salem S, Tharwat A, et al.
  Hospital response to COVID-19 a consensus: Report on Ain Shams University Hospital
  Strategy. [published online ahead of print, June 12, 2020]. ScienceOpen. doi:
  <u>https://doi.org/10.14293/S2199-1006.1.SOR-.PPD4QZX.v1</u>
- [6] Feng X, Li S, Sun Q, Zhu J, Chen B, Xiong M, Cao G. Immune-Inflammatory
  Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis. Front Med
  (Lausanne). 2020 Jun 9;7:301. doi: 10.3389/fmed.2020.00301. PMID: 32582743;
  PMCID: PMC7295898.
- [7] Usul E, Şan İ, Bekgöz B, Şahin A. Role of hematological parameters in COVID-19
  patients in the emergency room. Biomark Med. 2020 Sep;14(13):1207-1215. doi:
- 284 10.2217/bmm-2020-0317. Epub 2020 Jul 21. PMID: 32692248; PMCID: PMC7372996.

- [8] Chan AS, Rout A. Use of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte
- 286 Ratios in COVID-19. J Clin Med Res. 2020 Jul;12(7):448-453. doi: 10.14740/jocmr4240.
- 287 Epub 2020 Jun 25. PMID: 32655740; PMCID: PMC7331861.
- [9] Fois AG, Paliogiannis P, Scano V, Cau S, Babudieri S, Perra R, et al. The Systemic
- 289 Inflammation Index on Admission Predicts In-Hospital Mortality in COVID-19 Patients.
- 290 Molecules. 2020 Dec 4;25(23):5725. doi: 10.3390/molecules25235725. PMID:
- 291 33291581; PMCID: PMC7731255.
- [10] Wang C, Deng R, Gou L, Fu Z, Zhang X, Shao F, et al. Preliminary study to identify
- severe from moderate cases of COVID-19 using combined hematology parameters. Ann
- 294 Transl Med. 2020 May;8(9):593. doi: 10.21037/atm-20-3391. PMID: 32566620; PMCID:
- 295 PMC7290538

- 296 Table 1: Comparisons of patient demographic and clinical characteristics according to COVID-
- 297 19 severity, ICU admission and in-hospital mortality.

		(a)	(b)Severity			(c)I(	CU admissio	n	(d) In-hospital mortality		
V	ariable	Total (n=425)	Mild (n= 188)	Moderate to severe (n = 237)	P- value	Non-ICU (n =313)	ICU (n=112)	P- value	Survivors (n=385)	Non- survivors (n= 40)	P- value
Age	Mean ± SD	47.90 ± 17.08	40.84± 15.65	53.47± 16.10	≤ 0.001	44.70± 16.41	56.83 ± 15.75	≤ <b>0.001</b>	46.61± 16.90	$\begin{array}{c} 60.30 \pm \\ 13.60 \end{array}$	≤ <b>0.001</b>
	Range	13 – 94	13 – 94	17 - 92		13 – 94	22 - 91		13 – 94	35 - 85	
	Female	227 (53.4%)	110 (58.5%)	117 (49.4%)	0.061	174 (55.6%)	53 (47.3%)	0.132	205 (53.2%)	22 (55.0%)	0.832
Sex	Male	198 (46.6%)	78 (41.5%)	120 (50.6%)	-	139 (44.4%)	59 (52.7%)		180 (46.8%)	18 (45.0%)	
Severity	Mild	188 (44.2%)				184 (58.8%)	4 (3.6%)	≤0.001	188 (48.8%)	0 (0.0%)	_ ≤ 0.001
	Moderate to Severe	237 (55.8%)				129 (41.2%)	108 (96.4%)		197 (51.2%)	40 (100.0%)	
Hospital	Median (IQR)	10 (6 – 17)	7 (5 – 10)	14 (9 – 20)	- < 0.001	9 (6 – 13)	19 (9 – 22)	- < 0.001	10 (6 – 15)	18 (7 – 22)	0.010
(days)	Range	0-51	0 - 36	1 - 51	≥ 0.001	0-51	1 - 40	<u>≤ 0.001</u>	0-51	1 – 29	0.018
	Negative	313 (73.6%)	184 (97.9%)	129 (54.4%)	- 0 001				312 (81.0%)	1 (2.5%)	- ≤0.001
ICU	Positive	112 (26.4%)	4 (2.1%)	108 (45.6%)	- <u>≤ 0.001</u>				73 (19.0%)	39 (97.5%)	
_	Discharged	385 (90.6%)	188 (100%)	197 (83.1%)	< 0.001	312 (99.7%)	73 (65.2%)	≤ 0.001			
rate	Death	40 (9.4%)	0 (0.0%)	40 (16.9%)	- <u>≤</u> 0.001	1 (0.3%)	39 (34.8%)				

298

ICU, intensive care unit. Statistical significance set at 0.05.

# **Table 2:** Comparisons of patient comorbidities according to COVID-19 severity, ICU admission

## 300 and in-hospital mortality

		(b)Severity			(c)	ICU admiss	ion	(d) In-hospital mortality		
Comorb idity	(a) Total (n=425)	Mild (n= 188)	Modera te to severe (n = 237)	P-value	Non- ICU (n =313)	ICU (n=112)	P-value	Survivo rs (n=385)	Non- survivo rs (n= 40)	
COPD	78 (18.4%)	15 (8.0%)	63 (26.6%)	≤ 0.001	43 (13.7%)	35 (31.3%)	<b>≤ 0.001</b>	65 (16.9%)	13 (32.5%)	0.015
DM	129 (30.4%)	22 (11.7%)	107 (45.1%)	≤ 0.001	67 (21.4%)	62 (55.4%)	<b>≤ 0.001</b>	102 (26.5%)	27 (67.5%)	<b>≤ 0.001</b>
HTN	145 (34.1%)	26 (13.8%)	119 (50.2%)	≤ 0.001	80 (25.6%)	65 (58.0%)	<b>≤ 0.001</b>	119 (30.9%)	26 (65.0%)	<b>≤ 0.001</b>
CLD	17 (4.0%)	0 (0.0%)	17 (7.2%)	≤ 0.001	11 (3.5%)	6 (5.4%)	0.393	16 (4.2%)	1 (2.5%)	0.611
СКД	27 (6.4%)	2 (1.1%)	25 (10.5%)	<b>≤ 0.001</b>	13 (4.2%)	14 (12.5%)	0.002	20 (5.2%)	7 (17.5%)	0.002
IHD	42 (9.9%)	1 (0.5%)	41 (17.3%)	≤ <b>0.001</b>	16 (5.1%)	26 (23.2%)	<b>≤ 0.001</b>	32 (8.3%)	10 (25.0%)	0.001

301 COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HTN, hypertension; CLD,

302 chronic liver disease; CKD, chronic kidney disease; IHD, ischemic heart disease. Statistical

303 *significance set at 0.05.* 

## **Table 3:** Comparisons of patient laboratory findings according to COVID-19 severity, ICU

## 305 admission and in-hospital mortality

		(a)Total		(b)Severity		(c)	ICU admissi	on	(d) In	-hospital mor	rtality
Vari	able	(n=425)	Mild (n= 188)	Moderat e to severe	P-value	Non-ICU (n =313)	ICU (n=112)	p-value	Survivor s (n=385)	Non- survivors (n= 40)	P -value
НВ	Mean ± SD	12.01 ± 2.34	12.39 ± 2.19	11.70 ± 2.42	0.003	12.25 ± 2.23	11.32 ± 2.51	< 0.001	12.08 ± 2.32	11.33 ± 2.43	0.055
gm/dl	Range	2.9 - 17.3	5 – 17.3	2.9 – 16.6	0.005	5 – 17.3	2.9 – 16	≥ 0 <b>.</b> 001	2.9 - 17.3	6.6 – 16	0.055
PLT	Mean ± SD	248.02 ± 106.49	247.43 ± 90.64	248.49 ± 117.75	0.010	244.57 ± 96.21	257.66 ± 131.06	0.265	247.69 ± 104.01	251.13± 129.51	0.846
$\times 10^{3} \mu l$	Range	6 - 716	22 - 546	6 – 716	0.717	22 - 716	6 - 650	0.205	11 – 716	6 - 633	0.040
TLC	Median (IQR)	6.5 (4.5 – 9.8)	5.90 (4.46 – 7.63)	7.00 (4.62 – 11.30)	0.002	6.00 (4.40 – 8.30)	8.85 (5.05– 13.50)	< 0.001	6.20 (4.40 – 9.18)	11.50 (5.75 – 15.90)	- < 0.001
$\times 10^{3} \mu l$	Range	1.02 – 99.8	2.20 – 28.70	1.02 – 99.80	0.002	1.02 – 79.00	1.10 – 99.80	20.001	1.02 – 79.00	3.30 – 99.80	20.001
PNL	Median (IQR)	3.15 (2.2 – 4.9)	3.30 (2.46 – 4.30)	3.08 (2.10 – 5.70)	0.698	3.10 (2.20 – 4.40)	3.57 (1.90 – 9.05)	0.155	3.10 (2.20 – 4.60)	4.04 (2.10 – 11.50)	0 126
×10 <sup>3</sup> µl	$\frac{(100)}{10^{3}\mu l} \frac{4.9}{Range} \frac{4.9}{0.5 - 34.8} \frac{4.30}{9.64} \frac{5.70}{34.80} = 0.698 \frac{4.40}{9.05} \frac{9.05}{0.51 - 0.50 - 23.30} \frac{0.1}{34.80} \frac{0.51 - 0.50 - 23.30}{34.80} 0.51 $	0.155	0.50 – 24.80	0.90 – 34.80	0.120						
LYMPH	Median (IQR)	1.4 (0.9 – 2.08)	1.80 (1.30 – 2.30)	1.10 (0.70 – 1.60)	≤ 0.001	1.50 (1.10 – 2.20)	0.95 (0.70 – 1.40)	≤ 0.001	1.40 (0.90 – 2.10)	1.20 (0.78 – 1.60)	0.076
×10 µ1	Range	0.1 – 12.36	0.20 – 12.36	0.10 – 6.60		0.10 – 12.36	0.10 – 5.40		Survivor s (n=385)Non- survivors (n=40)12.08 $\pm$ 11.33 $\pm$ 2.322.432.9 - 17.36.6 - 16247.69 $\pm$ 251.13 $\pm$ 104.01129.5111 - 7166 - 6336.2011.50(4.40 -(5.75 -9.18)15.90)1.02 -3.30 -79.0099.803.104.04(2.20 -(2.10 -4.60)11.50)0.50 -0.90 -24.8034.801.401.20(0.90 -(0.78 -2.10)1.60)0.10 -0.20 -12.365.40160.77192.26(110.00 -(115.62 -263.33)352.08)8.33 -3.70 -1351.351055.002.292.63(1.46 -(1.70 -4.00)11.03)0.24 -0.77 -28.0096.80535.07682.48(304.33 -(371.61 -937.44)2620.45)27.50 -11.45 -9632.0015218.6420(125(7 - 68)152)1 - 7101 - 352		
PLR	Median (IQR)	162.5 (110 – 268.89)	134.67 (100.12– 183.91)	213.75 (125.00 – 344.00)	< 0 001	148.57 (108.85 – 232.31)	254.58 (125.30 – 387.30)	< 0 001	160.77 (110.00 – 263.33)	192.26 (115.62 – 352.08)	0.212
I LAX	Range	3.7 – 1351.35	14.67 – 805.00	3.70 – 1351.35	<u>- 0.001</u>	8.33 – 1025.00	3.70 – 1351.35	20.001	8.33 – 1351.35	3.70 – 1055.00	0.212
NI R	Median (IQR)	2.29 (1.5 – 4.17)	1.86 (1.25– 2.77)	2.58 (1.75 – 6.92)	< 0.001	2.17 (1.38 – 3.38)	3.74 (1.75 – 9.75)	< 0.001	2.29 (1.46 – 4.00)	2.63 (1.70 – 11.03)	0.028
IVEN	Range	0.24 – 96.8	0.24 – 16.00	0.45 – 96.80	<u>&gt;</u> 0.001	0.24 – 24.80	0.77 – 96.80	20.001	0.24 – 28.00	0.77 – 96.80	
сп	Median (IQR)	549 (308 – 965.45)	447.68 (280.35- 718.95)	669.67 (348.92 – 1558.25)	< 0.001	507.50 (287.00 – 852.62)	737.55 (409.51 – 2117.54)	< 0.001	535.07 (304.33 – 937.44)	682.48 (371.61 – 2620.45)	0.055
511	Range	11.45- 15218.64	43.10- 2576.00	11.45- 15218.64	<u>≤ 0.001</u>	27.50 – 5580.00	11.45 – 15218.64	<u>≤ 0.001</u>	27.50 – 9632.00	11.45 – 15218.64	0.050
CRP	Median (IQR)	24 (8 - 83)	12 (5 – 25)	64 (18 -129)	< 0.001	16 (6 - 48)	103 (46 – 152)	< 0.001	20 (7 - 68)	125 (59 – 152)	< 0.001
mg/L	Range	1 – 710	2 - 164	1 – 710	<u>≤</u> 0.001	1 – 372	1 – 710	<u> </u>	1 – 710	1 - 352	≤ <b>0.001</b>

HB, hemoglobin; PLT, platelets; TLC, total leucocytic count; PNL; neutrophils; LYMPH, lymphocytes;
PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; SII, systemic immuneinflammation index (neutrophil\*platelet to lymphocyte ratio); CRP, C-reactive protein. Statistical
significance set at 0.05.

- **Table 4:** Recommended cut-off values for the prediction of COVID-19 severity, need for ICU
- 311 admission and in-hospital mortality.

	AUC	Cut off	Sensitivity %	Specificity %	PPV %	NPV %
Disease severity						
PLR	0.640	>185	51.52	80.20	71.8	62.8
NLR	0.700	>4.33	47.47	95.05	89.1	62.3
SII	0.669	>1012.36	46.46	93.07	86.8	63.9
CRP (mg/L)	0.707	>12	65.66	69.31	67.7	67.3
ICU admission						
PLR	0.580	>300	38.10	89.87	50.0	84.5
NLR	0.727	>4.5	59.52	83.54	49.0	88.6
SII	0.717	>668.57	71.43	63.92	34.5	89.4
CRP (mg/L)	0.763	>115	54.76	94.30	71.9	88.7
In-hospital mortality						
NLR	0.751	>4.5	65.0	78.89	25.5	95.3
CRP (mg/L)	0.812	>141	70.0	95.56	63.6	96.6

312 PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; SII, systemic immune-

313 inflammation index (neutrophil\*platelet to lymphocyte ratio); CRP, C-reactive protein; AUC, area

314 *under the curve; NPV, negative predictive value; PPV, positive predictive value.* 

# **Table 5:** Logistic regression analysis for predictors of COVID-19 severity, ICU admission and in-

# 316 hospital mortality.

		Uni-va	riate		<b>Multi-variate</b>					
Diana any mitry	P-value	Odds ratio 95% C.I		[. for OR	D voluo	<b>Odds ratio</b>	95% C.I. for O			
Disease severity		( <b>OR</b> )	Lower	Upper	P-value	( <b>OR</b> )	Lower	Upper		
PLR	$\leq$ 0.001	4.407	2.882	6.738	0.452	1.332	0.630	2.817		
NLR	$\leq$ 0.001	8.095	4.347	15.075	0.616	1.335	0.432	4.124		
SII	$\leq$ 0.001	7.808	4.191	14.547	0.032	3.143	1.101	8.976		
CRP	$\leq$ 0.001	6.017	3.893	9.300	0.166	1.533	0.837	2.808		
ICU admission										
PLR	$\leq$ 0.001	4.757	2.880	7.857	0.069	2.271	0.939	5.491		
NLR	$\leq$ 0.001	5.111	3.132	8.342	0.035	2.662	1.072	6.611		
SII	$\leq$ 0.001	2.195	1.416	3.401	0.067	0.414	0.161	1.062		
CRP	$\leq$ 0.001	7.617	4.465	12.995	0.007	2.902	1.342	6.273		
In-hospital mortality										
NLR	0.001	3.273	1.673	6.403	0.766	1.149	0.461	2.863		
CRP	$\leq$ 0.001	10.332	5.024	21.248	0.007	3.988	1.460	10.892		

317 PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; SII, systemic immune-

318 inflammation index (neutrophil\*platelet to lymphocyte ratio); CRP, C-reactive protein; C.I,

319 *confidence interval. Statistical significance set at 0.05.* 



# 320

# 321

Figure1: Receiver-operating characteristic curve for prediction of disease severity



# 322

323

Figure 2: Receiver-operating characteristic curve for prediction of ICU admission



**Figure 3:** Receiver-operating characteristic curve for prediction of in-hospital mortality